Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. (ARMP) is a publicly listed company on US equity markets.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

The company reports net loss of $115.35M.

Key metrics include a return on equity of 37.0%, a debt-to-equity ratio of -1.22.

Use FINOTAUR to track ARMP's price action, review fundamentals, and stay current with company news — all in one research dashboard.